Showing posts with the label Ionis Pharmaceuticals

Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development

IndustryPRwire -- Ionis Pharmaceuticals announced that the biopharmaceutical company AstraZeneca has licensed ION455, an investigational antisense medicine being developed as a potential treatment f…

Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx)

Ionis Pharmaceuticals and its wholly owned subsidiary Akcea Therapeutics, Inc., today announced that Pfizer has initiated a Phase 2b study of vupanorsen (AKCEA-ANGPTL3-LRx) in statin-treated patient…

Ionis' inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis

Ionis Pharmaceuticals, Inc announced today that data from a clinical trial of IONIS-ENAC-2.5Rx demonstrated a significant decrease in the expression of epithelial sodium channel (ENaC) in subjects wi…

Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics

Ionis Pharmaceuticals, Inc today announced the successful completion of its transaction to acquire 100% ownership of Akcea Therapeutics, Inc. The combination of Ionis and Akcea accelerates the next p…
Subscribe Our Newsletter